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Chronic kidney disease mineral bone disorder
Abstract 
Chronic kidney disease – mineral bone disease (CKD-MBD) is a syn-
drome defined as a systemic mineral metabolic disorder associated with 
CKD. The term renal osteodystrophy, as a part of CKD-MBD, indicates a 
pathomorphological concept of bone lesions. High morbidity and mortality 
of CKD patients is a consequence of CKD-MBD. The pathogenesis of this 
syndrome is not completely understood, but undoubtedly the development 
of mineral and bone disorder begins in the earliest stages of CKD. The di-
agnosis is made by non-invasive methods (biochemistry, x-ray, ultrasound, 
etc.) and bone biopsy as an invasive method. In addition to new drugs, e.g. 
non-calcium phosphate binders, vitamin D analogs, calcimimetics, preven-
tion and treatment is still a major challenge for the nephrologist. In this 
article we will briefly discuss the pathophysiology, diagnosis, prevention and 
treatment of CKD-MBD.
Chronic kidney disease (CKD), defined by structural or functional kidney abnormalities for more than three months, is a significant 
global health problem. Based on kidney function, i.e. glomerular filtra-
tion rate (GFR), CKD is classified in five stages: stage 1: GFR > 90 ml/
min, stage 2:  GFR 60-89 ml/min, stage 3: GFR 30-59 ml/min, stage 
4: GFR 15-29 ml/min and stage 5:  GFR ≤15 ml/min.  CKD is associ-
ated with multiple organ dysfunctions.  Due to    the high prevalence 
of cardiovascular disease, the mortality of CKD patients is very high. 
In addition to traditional risk factors for cardiovascular disease (hyper-
tension, diabetes, hyperlipidemia), there are a many other non-tradition-
al risk factors. Mineral disturbance is one of the most important non-
traditional risk factors  (1). 
The kidney has a central role in the maintenance of serum calcium 
and phosphorus levels through tubular reabsorption mechanisms. Par-
athyroid hormone (PTH), vitamin D, i.e. calcitriol and fibroblast 
growth factor 23 (FGF 23) are important factors in the regulation of 
calcium and phosphorus metabolism. These factors are also involved in 
bone metabolism and are interrelated, i.e. they are the basis for the bone-
kidney axis. In patients with impaired kidney function, even in the 
early stages of impaired metabolism of calcium, phosphorus and regula-
tory hormones occur. The consequence is bone disease (2).
Bone disease, known as renal osteodystrophy, was recognized as a 
complication of chronic renal failure (today CKD stage 5) in the early 
of 1960s (3). Since then, great advances have been made in diagnosis, 
prevention and treatment. At the same time, it has been recognized that 
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bone disease is only one of a broad spectrum of imbal-
ances that manifests itself in pathological changes in the 
bones and very often in pathological changes outside of 
the skeleton, particularly heart and vessels (4). In 2006, a 
new definition came into use: chronic kidney disease-
mineral and bone disorder (5). It describes a very broad 
clinical syndrome, i.e. a systemic disorder of mineral and 
bone metabolism due to CKD, manifested by abnormal-
ities of calcium, phosphorus, PTH, vitamin D, FGF 23, 
bone diseases and significant pathologic calcification (Ta-
ble 1). 
The pAThogenesis of CKD-MBD
The pathogenesis of CKD-MBD is not completely 
understood, but based on broad basic and clinical re-
search it is accepted that a central role in pathogenesis is 
phosphorus (better to say phosphate, since we measure 
phosphate in a blood sample) retention (Table 2) (6).  Due 
to impaired kidney function, there is reduced phosphate 
excretion that leads to phosphate retention. As a result of 
that phosphate retention, there is increased secretion of 
FGF 23 on one hand and impaired synthesis of calcitriol 
on the other. Reduced synthesis of calcitriol is the result 
of reduced renal mass, phosphate retention and the effect 
of increased FGF 23 level. A low level of calcitriol to-
gether with phosphate retention leads to hypocalcaemia. 
The net effect is increased synthesis and secretion of PTH 
(Figure 1). In the early stages of CKD hyperphosphatemia 
and hypocalcaemia are counteracted by increased PTH 
concentrations. Therefore, in many patients normal levels 
of calcium and phosphate are present, but the price is a 
high PTH level. As with other endocrine organs, para-
thyroid gland (PTG) overactivity is associated with hy-
pertrophy and hyperplasia. The characteristic of PTG 
hyperplasia in CKD patients is initially diffuse and poly-
clonal, after which nodular change appear, i.e. monoclo-
nal hyperplasia, with a significant reduction of vitamin D 
and calcium receptors (7, 8). The result is secondary hy-
perparathyroidism. In this brief description of the patho-
genesis of secondary hyperparathyroidism it must be 
emphasized that, based on very recent research, FGF23 
and its co-receptor klotho (transmembrane receptor) 
probably have the most important roles. A reduced num-
ber of klotho receptors in kidney and parathyroid glands 
and an increased level of FGF23 leads to hypocalcemia, 
hyperphosphatemia, reduced level of calcitriol and PTH 
overactivity (2, 6).
Increased bone turnover with a tendency to fracture is 
the result of hyperparathyroidism (6, 9).
The other extreme of bone disease in CKD is low bone 
turnover, i.e. adynamic bone disease. Until the early 
1980s, aluminum intoxication was the main cause of low 
bone turnover disease in CKD patients. Today,  the risk 
factors for this form of bone disease in CKD patients are 
patient age, diabetes mellitus, inadequate treatment with 
active vitamin D analogs or calcium- based phosphate 
binders (i.e. excess calcium load), etc. (2, 9). Bone pain 
and the risk of fractures  are also manifestations of this 
form of renal osteodystrophy. 
Finally, soft tissue calcification and vascular calcifica-
tions are the results of increased phosphate levels. There 
is much data to confirm the possibility of transforming 
the smooth muscle cells in the arterial wall into an osteo-
blast-like cell. Vascular calcification, as part of CKD-
MBD syndrome, is different from that seen in the gen-
eral population. In the aging general population 
calcification of intima occurs, while in CKD patients cal-
cification of arterial media is more prominent. The result 
is greater vascular stiffness, hypertension, and left ven-
tricular hypertrophy (10, 11).
CliniCAl MAnifesTATion  
of CKD-MBD
Bone and mineral disturbance in CKD patients can 
be asymptomatic for a long time. The first manifestation 
of CKD-MBD is biochemical. Bone and muscle pain, 
weakness and fractures of bone and sometimes avascular 
necrosis can be seen in later stages of the disease. The 
incidence of bone fractures is very high in CKD patients. 
It is twice as high compared to patients without CKD.  In 
severe forms of CKD-MBD osteoclastomas, or brown 
tumors resulting from PTH- stimulated osteoclastic ac-
tivity can be seen (12).  Calcific uremic arteriolopathy, a 
condition in which small cutaneous blood vessels are cal-
cified, is often lethal and is seen in severe secondary hy-
perparathyroidism (3, 9).
Table 1
KDIGO definition of CKD MBD and renal osteodystrophy (ROD) , (adapted from ref. 5).
CKD MBD,  a systemic disorder of bone and mineral metabolism due to CKD, manifested by following:
             • Abnormalities of calcium, phosphorus, PTH, vitamin D
             • Abnormalities in bone turnover, mineralization and volume
             • Vascular  or other soft tissue calcification 
ROD, a bone disease in CKD with the following characteristics:
             • Alteration of bone morphology 
             • One measure of the skeletal component of CKD MBD quantifiable by histomorphometry of bone biopsy
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DiAgnosis of CKD-MBD
CKD-MBD is asymptomatic for a long time. There-
fore, diagnosis is based on biochemistry, radiology and 
finally on a bone biopsy. The key measurements used in 
routine CKD-MBD screening are calcium, phosphate, 
alkaline phosphatase and PTH.  Based on the Kidney 
Disease Outcomes Quality Initiative (KDOQI) and the 
Kidney Disease Improving Global Outcomes (KDIGO) 
guidelines, these measurements should be routinely mon-
itored beginning at stage 3 CKD.  (1, 5, 13) Prevention 
and treatment should be guided by these measurements. 
A physician involved in the treatment of CKD patients 
should interpret them carefully. Total calcium, but not 
ionized calcium, should be checked regularly. The so-
called corrected calcium can be calculated by adding 0.2 
mmol to the total calcium for every 1 g/L decrease in the 
albumin level below 40 g/L. The calcium concentration 
cannot be a guide for the underlying CKD-MBD (1). 
There is diurnal and postprandial variation of the phos-
phate level. Therefore, the phosphate level should be 
checked on an empty stomach. Total alkaline phosphatase 
is not the best marker for bone turnover, but an immu-
noassay for bone specific alkaline phosphatase as better 
marker is not in standard practice.
There is no doubt that measurement of PTH is most 
important in the diagnosis of CKD-MBD. Once again, 
the results should be interpreted carefully. The routine 
assay for PTH is so-called intact PTH. With this assay, 
also called the second generation, some fragments (C-
terminal) antagonistic to intact PTH are detected. There-
fore the optimal level of PTH is not known, but it should 
be more than three times the upper limit of normal. It is 
more important to check the PTH level a few times per 
year in CKD patients (there are some suggestions that it 
should be done monthly) and to follow the trend of the 
PTH level (1, 13).
Imaging by X-ray, ultrasound, computed tomography 
and magnetic resonance of the skeleton is relatively insen-
sitive for a diagnosis of CKD-MBD. (3, 9) The results of 
bone densitometry should also be interpreted carefully 
and it cannot distinguish between osteoporosis and 
CKD-MBD (14). The characteristic X-ray changes in 
CKD-MBD are the phalangeal tufts, subperiostal bone 
erosion (Figure 2), lineal osteosclerosis of the spine, and 
lucent areas of the long bones (very often brown tumor). 
In our experience ultrasound is very useful in detecting 
PTG size and shape, i.e. to make a diagnosis of PTG 
hyperplasia and to distinguish diffuse and nodular hyper-
plasia. Nodular hyperplasia is a more severe form of hy-
perplasia (Figure 3) (7, 8).
Figure 1. Pathogenesis of secondary hyperparathyroidism. (FGF 23 
fibroblast growth factor 23).
Figure 2. Subperiostal resorption of the  bone of the middle phalanx 
(arrows).
Figure 3. Parathyroid sonography ( PT parathyroid gland, T thyroid 
gland). 
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Bone biopsy is the gold standard for a diagnosis of the 
pattern of bone disease, but it is not available everywhere, 
and it is invasive and time consuming. In more recent 
guidelines there is new classification system for bone his-
tomorphometry, known as turnover mineralization and 
volume (TMV). Instead of the terms of adynamic bone, 
mixed or mild osteodystrophy, and high turnover bone 
disease (osteitis fibrosa), the TMV classification is made 
up of different descriptors: T (from low to high), M (from 
normal to abnormal), and V (from low to high). The bone 
biopsy should be done if a prediction by non-invasive 
methods of bone changes is very weak (1, 15).
prevenTion AnD TreATMenT of 
CKD-MBD
The central tenets of treatment of CKD-MBD are cor-
rection of hypocalcaemia, reducing hyperphosphatemia, 
and maintaining optimal concentration of calcitriol. Un-
fortunately, it is still difficult to control mineral distur-
bance, including increased PTH synthesis and secretion. 
In the last ten years, several guidelines for the diagnosis 
and treatment of CKD-MBD have been published (1, 5, 
13). There are many differences between guidelines, and 
the majority of statements in these guidelines are based on 
evidence graded as poor or moderate (16, 17, 18). How-
ever, treatment paradigms today have centered on the 
adoption of KDOQI or KIDIGO guidelines (Table 2).
phosphorus ConTrol
Dietary phosphorus restriction to less than 1000 mg/
day is recommended. Food with high phosphorus content 
(high phosphorus to protein ratio) and food and drinks 
with a high level of phosphate additives, such as some soft 
drinks, e.g. coca cola,  and fast and processed foods 
should be avoided. Dietary restriction is insufficient in the 
majority of patients, particularly those on dialysis. They 
must use phosphate binders. Calcium-based binders are 
effective, but hypercalcemia can be a possible side effect. 
A combination of calcium acetate and magnesium car-
bonate has several advantages. Magnesium can reduce the 
risk of soft tissue calcification. Sevelamer carbonate, a 
non-calcium-based phosphate binder is effective, with the 
possibility of decreasing low-density lipoprotein choles-
terol levels. Lanthanum carbonate is also an effective 
phosphate binder, but it is still unavailable in many coun-
tries. Phosphate binders should be taken at each meal. 
High pill burden is a major reason for poor adherence by 
CKD patients.  Dialysis adequacy is important in reduc-
ing phosphate level, and even more important is more 
frequent dialysis, e.g. short daily or long nocturnal hemo-
dialysis (19). 
vitamin D Therapy
Vitamin D or analogs are often used in CKD patients 
to prevent and treat secondary hyperparathyroidism. For 
many years, the most commonly used agent was calcitri-
ol (in some European countries it was alfacalcidol). Today, 
paricalcitol, a less calcemic vitamin D analog also called 
selective vitamin D receptor activator, is used more fre-
quently (6). 
Calcimimetics
A calcimimetic, cinacalcet, is an allosteric activator of 
calcium-sensing receptors. Cinacalcet offers a new thera-
peutic modality by reducing parathormone synthesis se-
cretion and hypercalcemia. On the other hand, hypocal-
caemia could be a negative side effect. Vitamin D analogs 
and calcimimetics can be used together (6, 13).   
surgery
In some patients, even with new drugs, severe hyper-
parathyroidism could be present and surgery becomes 
inevitable. Total parathyroidectomy, with or without au-
totransplantation, or a subtotal parathyroidectomy, could 
be performed. If surgery is indicated, very often in pa-
tients with severe nodular PTG hyperplasia, it should be 
done before a kidney transplant (8, 20).
ConClusion
CKD-MBD could be a significant cause of morbidity 
and morbidity in CKD patients. The prevention and 
Table  2
PTH, calcium and phosphorus target values according to KDOQI an KDIGO gudelines.
CKD stage
Calcium
mmol/l 
 
Posphorus
mmol/l
PTH 
pg/ml
KDOQI KDIGO KDOQI KDIGO KDOQI KDIGO
3 Normal range Normal range 0,86-1,47 Normal range 35-70 Normal range
4 Normal range Normal range 0,86-1,47 Normal range 70-110 Normal range
5 2,1-2,4 Normal range 1,12-1,76 Toward the normal range 150-300
2-9 time the up-
per normal limit 
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treatment of CKD-MBD is still a major challenge for the 
nephrologist (8). New international and many national 
guidelines might be helpful, but one should remember 
that guidelines should inform but not dictate, guide but 
not enforce, and support but not restrict (21).
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